Related Experiment Video

Updated: Jun 24, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Evidence-based prescribing and adherence to antiplatelet therapy--how much difference do they make to patients with

Steen Husted1

  • 1Medical-Cardiological Department A, Aarhus University Hospital, Aarhus C, Denmark. steehust@rm.dk

International Journal of Cardiology
|March 14, 2009
PubMed

Insights

Physician uptake of antiplatelet guidelines and patient adherence are crucial for preventing cardiovascular events. Improving adherence requires addressing both physician and patient factors to enhance secondary prevention strategies.

Area of Science:

  • Cardiology
  • Pharmacology
  • Public Health

Background:

  • Antiplatelet therapy is essential for secondary prevention in atherothrombotic diseases.
  • International guidelines exist for optimal antiplatelet agent use.
  • Atherothrombosis encompasses acute coronary syndromes, cerebrovascular disease, and peripheral arterial disease.

Purpose of the Study:

  • To quantify physician uptake of antiplatelet guideline recommendations.
  • To assess patient adherence to prescribed antiplatelet treatments.
  • To explore consequences of non-adherence and strategies for improvement.

Main Methods:

  • Literature review of published studies.
  • Analysis of physician prescribing patterns versus guidelines.
  • Evaluation of patient adherence rates.
  • Examination of factors influencing adherence.

Main Results:

  • Data on physician adherence to guidelines is variable.
  • Patient adherence rates to antiplatelet therapy require further investigation.
  • Non-adherence has significant negative consequences for secondary prevention.

Conclusions:

  • Optimizing antiplatelet therapy requires improved physician guideline adherence.
  • Enhancing patient adherence is critical for reducing cardiovascular events.
  • Collaborative strategies involving physicians and patients can improve treatment outcomes.

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...